Rover

RoverMed BioSciences is a biotechnology company focused on the development of a proprietary platform for the targeted delivery of precision medicines. Their "Rover" (Re-targeted Optimized Vector for Enhanced Release) technology utilizes non-toxic, targeted nanoparticles to deliver therapeutic payloads, such as siRNA, DNA, and small molecules, directly to diseased cells. By utilizing targeting ligands like the AS1411 aptamer to bind to cell-surface nucleolin, the platform aims to enhance therapeutic efficacy while minimizing off-target toxicity. The company's pipeline primarily targets hard-to-treat cancers, including pancreatic and breast cancer, where traditional delivery methods often fail.